a Objective: To compare birth weight and weight gain in HIV-exposed, uninfected (HEU) infants up to 24 months old, who enrolled in the Malawian national HIV care clinic (HCC) programme either before or after Option Bþ (OBþ) was implemented.
Introduction
Scaling up prevention of mother-to-child transmission (PMTCT) interventions has drastically lowered the number of HIV-infected children worldwide. Without intervention, the likelihood of mother-to-child transmission (MTCT) of HIV ranges from 15 to 45%, but effective PMTCT interventions can reduce this risk to under 5% [1] . In Malawi, PMTCT coverage remained sub-optimal until 2011, when the Ministry of Health (MoH) pioneered implementation of universal lifelong combination antiretroviral therapy (ART) for pregnant and breastfeeding women regardless of their CD4 þ cell count or clinical stage ['Option Bþ' (OBþ)] [2] . As a consequence of the scale-up of OBþ, ART coverage in pregnant and breastfeeding women has increased and MTCT risk of HIV declined [3] resulting in a growing number of HIV-exposed, uninfected (HEU) children.
Although scaling up of PMTCT has greatly improved maternal health, there is concern that in-utero exposure to antiretrovirals may negatively affect birth outcomes, growth and development of infants born to HIV-infected mothers [4] [5] [6] . Some studies reported that in-utero antiretroviral exposure is associated with low birth weight [6] [7] [8] ; others found no such association [9] [10] [11] [12] . Some studies found differences in weight gain [13] [14] [15] [16] [17] between HEU infants and healthy controls. A systematic review published in 2014 was inconclusive about the effect of inutero HIVand antiretroviral exposure on postnatal weight gain of HIV-exposed infants [4] .
Although some studies have examined the association between in-utero ART exposure and adverse birth outcomes in the OBþ era [18, 19] , no study has investigated if OBþ affects the growth of HEU infants. We investigated the impact of OBþ on postnatal weight gain of Malawian HEU infants in the first 24 months of their lives under programmatic circumstances.
Methods

Study setting
Malawi's MoH provides integrated services for HIVexposed infants in the national HIV care clinic (HCC) programme under Integrated HIV Management guidelines [20] as previously described [21] . Programme data suggest that most known HIV-exposed infants are enrolled and managed in this programme with regular clinic follow-up from 6 weeks after birth [20, 22] .
Study design and inclusion criteria
We included infants born to an HIV-infected woman, who enrolled in the HCC programme between January 2010 and December 2014 at any of the 21 large health facilities in central and southern Malawi that participated in our study to evaluate the implementation of OBþ (www.umoyoplus.org) (Fig. 1) . The facilities included 13 district hospitals, two central hospitals, three faith based hospitals, and three large health centres. All infants who had a negative HIV test result were included. HIVinfected infants diagnosed positive at any point during follow-up and infants with unknown HIV status were excluded. We also excluded infants with missing birth date, birth weight or sex, and infants with no follow-up weight measurement. Infants were included in the analysis from enrolment until the last recorded followup visit.
Data collection, preparation and management
Registration and follow-up data for HIV-exposed infants enrolled in the HCC programme are recorded on standardized paper-based treatment cards stored at health facilities. At each visit, trained healthcare workers measure infant's weight with a mechanical scale that is calibrated daily [23] . Routinely collected data were digitized from the treatment cards, followed by double data entry and cleaning. Records were de-duplicated using probabilistic linkage [21] .
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Number of HIV-exposed infants enrolled in the HIV care programme: 16, 200 Included in the study: 6,845 Definitions and outcomes Programmatic outcomes at the end of follow-up were defined as under follow-up, died, discharged uninfected, transferred out to another health facility, or lost to followup (LTFU). LTFU was defined as missing a clinic appointment for more than 60 days and not returning to care. ART was defined as a combination of at least three antiretroviral drugs. Before OBþ, women eligible for ART received a combination of stavudine, lamivudine and nevirapine. Women not eligible for ART received zidovudine monotherapy during pregnancy followed by zidovudine þ lamivudine dual therapy or single-dose nevirapine during labour. During OBþ, all women received a combination of tenofovir, lamivudine and efavirenz.
We defined birth period as pre-Option Bþ (pre-OBþ) or Option Bþ (OBþ) using the date each facility switched to OBþ. Infants born within a few months of the health facility's switch to OBþ were classified into the OBþ group, although they were not necessarily exposed to OBþ from the beginning of pregnancy. We converted birth weight and weight measurements into age and sex-adjusted z scores, based on the WHO 2006 standard [24] .
The primary outcome was postnatal weight gain in the first 24 months of life, assessed with weight-for-age z scores (WAZ). We also assessed factors associated with birth weight (WAZ at birth).
Statistical analyses
Baseline characteristics by birth period were compared with Wilcoxon rank-sum tests for continuous variables and Chi-square tests for categorical variables. We used linear regression to investigate differences in WAZ at birth, and mixed effects models to examine changes in WAZ over time (with a random effect on the infant and fixed effects on the intercept and explanatory variables). We used a third order polynomial transformation for age (in months) because weight gain is not linear. We tested the effect of covariates on WAZ at birth and during follow-up, and for an interaction between the polynomial transformation of age and birth period, with a likelihood ratio test. We also did stratified analyses by birth period to identify predictors of postnatal weight gain in each birth period. All available weight measurements from enrolment up to the last follow-up visit (including infants who were LTFU, transferred out or who died) were included in the analysis. All mixed effects models were adjusted for the polynomial transformation of age. In multivariable models, we adjusted for infant's gender, birth weight (<2.5 kg, !2.5 kg), type of health facility (health centre, faith-based hospital, district hospital, central hospital), and infant antiretroviral exposure during pregnancy or labour (none, mono or dual-therapy, ART <4 weeks, or ART !4 weeks at any stage).
Results from models are presented as differences in WAZ with 95% confidence intervals. Factors affecting birth weight There were no statistically significant differences in WAZ at birth among infants born before and after introduction of OBþ (Table 2) . Infants enrolled at a health centre or district hospital had significantly higher WAZ at birth than infants enrolled at a central hospital. Exposure to antiretrovirals during pregnancy or labour, irrespective of regimen or duration, had no significant effect on WAZ at birth.
If the analysis was stratified by birth period, associations were similar (Appendix , Tables A2a and A2b , http:// links.lww.com/QAD/B326). In the adjusted analysis the association between type of facility and WAZ at birth was however only present in the OBþ group.
Factors affecting postnatal weight gain
The interaction between polynomial transformation of age and birth period was not significant in univariable analysis (P ¼ 0.287) and was therefore not included in the model. Postnatal WAZ was higher in the OBþ group (difference 0.211, 95% CI 0.117-0.306; P < 0.0001) irrespective of age after adjusting for gender, birth weight, facility type and maternal antiretroviral exposure (Table 3 and Fig. 2 ). Other predictors of WAZ over time included a birth weight of at least 2.5 kg and female gender. Infant's exposure to antiretrovirals during pregnancy or labour, regardless of type of regimen or length of exposure, had no significant impact on postnatal WAZ in the univariable analysis. Infants exposed to ART for at least 4 weeks during pregnancy had significantly lower WAZ in the first 24 months of life in adjusted analyses. However, when we stratified the analysis by birth period (Appendix , Tables 3a and 3b , http://links.lww.com/ QAD/B326), only infant gender and type of health facility had a significant effect on WAZ in the OBþ period, and there was no effect of type and duration of antiretroviral exposure on WAZ in either birth period.
Discussion
The proportion of infants exposed to ART during pregnancy or labour increased significantly after OBþ was implemented, and infants were exposed to ART for a longer time. WAZ was similar at birth among HEU ART was defined as a combination of at least three antiretroviral drugs. Before OBþ, women eligible for ART received a combination of stavudine, lamivudine, and nevirapine. Women not eligible for ART received zidovudine monotherapy during pregnancy followed by zidovudine þ lamivudine dual therapy or single-dose nevirapine during labour. During OBþ, all women received a combination of tenofovir, lamivudine and efavirenz.
b
Represents women who missed some ART visits to the health facility.
c Infants who missed a clinic appointment for more than 60 days and did not return to care.
M P values from Wilcoxon rank-sum tests (continuous variables) and Chi-square tests (categorical variables).
infants born before and after OBþ, but postnatal weight gain was higher in HEU infants born in the OBþ period than infants born in the pre-OBþ period.
Prolonged exposure to ART, more common in the OBþ period, may increase adverse pregnancy outcomes like preterm delivery and low birth weight [25] . The European collaborative study found an association between prematurity and ART exposure, for all types of regimens [9] . Some studies from resource-limited settings found that lower birth weight was associated with in-utero ART exposure [8, 26, 27] but did not seem to impair postnatal growth [8, 27, 28] .
We found that neither the type of antiretroviral regimen, nor length of in-utero ARTexposure was associated with WAZ at birth in HEU infants consistent with other African studies [12, 14, 29] . Most infants in our study were exposed to ART in utero, so a potential negative effect of ART was probably counter balanced by the favourable
Weight gain of HIV-exposed, uninfected children under 'Option BR' Msukwa et al. 2205 Table 2 . Linear regression analysis of weight-for-age z scores at birth, birth weight (n U 6845). The multivariable model assessed the association between WAZ and birth period adjusting for all independent variables and the polynomial transformation of age.
M P values from likelihood ratio test.
immunological and virological response to ART in the pregnant woman, resulting in improved maternal health that benefits infants' outcomes. However, we had no data on CD4 þ cell counts and viral loads during pregnancy.
Disentangling the exact effect of the birth period, the type and length of ARTexposure, and the CD4 þ cell count on WAZ at birth and longitudinal weight gain was not possible. Since we compared the pre-OBþ period with the OBþ period, the number of drugs and the types of antiretroviral regimens depended on the birth period. During the pre-OBþ period, women who were on combination ART had low CD4 þ cell counts or were in an advanced stage of the disease. The association of being on ARTat least 4 weeks with slower weight gain may therefore be driven by observations in the pre-OBþ period. However, we could not confirm this hypothesis in stratified analyses, possibly because of the low sample size.
Since we did not capture the date of ART initiation, we also do not know whether the women had started ART preconception, in the first trimester, or in the last two trimesters. This is a relevant limitation because a study from Brazil showed that birth weight was lower in infants with exposure to ART in the first trimester than later exposure or no exposure to ART in utero [30] . Discrepant findings between studies may be related to differences in the populations studied, variations in antenatal and postnatal care and contrasting study designs (e.g. adjustment for different confounders and different selection criteria).
A number of additional factors were associated with postnatal WAZ. Contrary to other studies [31] [32] [33] [34] [35] , we found no significant differences in WAZ at birth between boys and girls. However, girls had higher postnatal WAZ than boys, in agreement with a study done in South Africa [31] . HEU infants with normal weight at birth (!2.5 kg) had higher postnatal WAZ than those with low birth weight (<2.5 kg) consistent with previous studies [17, 36, 37] .
We faced several limitations. The first was our inability to determine if OBþ itself spurred improvement in postnatal weight gain, or if other factors were responsible. In developing countries, poverty, socio-economic conditions, malnutrition, and poor health affect the growth and development of children under the age of 5 [38] . Socioeconomic, environmental and immunological factors are also associated with undernutrition in children born to HIV-infected mothers [17, 39, 40] . We did not adjust for these factors because we had no data. Second, in routine clinical care LTFU is often high. Weight measurements are biased by LTFU, because children with impaired weight gain are more likely to be LTFU and to die. Therefore, we anticipate that weight gain was particularly overestimated in the pre OBþ group. Third, we only included large health facilities, so our findings may not be representative of infants from smaller rural health centres. Fourth, birth length was not recorded, and height was sporadically recorded during follow-up visits, so we could not compare length/height-for-age and weight-for-length/height z scores over time. Fifth, we determined birth period according to infant's date of birth. When a clinic implemented OBþ, all women attending antenatal care, including those who were already on zidovudine prophylaxis, were instructed to switch to triple life-long ART at their next visit. In practice, however, the transition to OBþ may have taken some time, and infants born soon after the switch to OBþ were not exposed to the policy for the entire period. Therefore, inclusion of HEU infants born in the transition period in the OBþ group underestimates the positive effect of OBþ on weight gain. Finally, we excluded a large number of infants due to missing data whose characteristics were different from those included.
Our study has a number of strengths. We believe we are the first to assess weight gain in routine care during the first 24 months of life for HEU infants in the OBþ era. Our study had a large sample size, and followed HEU infants over a long period. Our study facilities were geographically diverse and included a variety of clinical settings.
Our finding of better postnatal weight gain among HEU infants born in the OBþ period is encouraging considering the widespread implementation of OBþ. To confirm our findings, future studies should include small health centres and account for socioeconomic characteristics, infant feeding practices, and maternal disease progression. OBþ increased exposure to ART during pregnancy. The increase did not affect birth weight, and seems to have improved postnatal weight gain in HEU infants, possibly because OBþ also improved mothers' health.
